A quiet revolution in diabetes care is unfolding north of the US border. Canada has successfully introduced a generic version of semaglutide, the active ingredient in Ozempic and Wegovy, slashing costs by over 70% compared to American prices. This development highlights a stark transatlantic divide: while the United States remains shackled to patent protections and high drug prices, the UK’s National Health Service (NHS) has long employed a model of cost negotiation and bulk purchasing that makes essential medicines broadly accessible. The contrast is not merely economic; it is a matter of public health and equitable access.
Canada’s move is a direct challenge to the pharmaceutical industry’s pricing strategies. By allowing generic competition, Canada has bypassed the patent thicket that keeps US prices artificially high. A month’s supply of generic semaglutide in Canada costs approximately $150 CAD, compared to over $900 USD in the United States. This disparity forces American patients to ration doses or forgo treatment, with devastating consequences for diabetes management and obesity-related health outcomes.
The UK’s NHS model offers a template for what can be achieved when healthcare is treated as a public good rather than a market commodity. The NHS negotiates drug prices directly with manufacturers, leveraging its single-payer power to secure discounts that are often 50% to 80% lower than US list prices. For semaglutide, the NHS pays around £70 per month. This is not charity; it is strategic procurement. The NHS also conducts rigorous cost-effectiveness assessments through the National Institute for Health and Care Excellence (NICE), ensuring that taxpayer money is spent on treatments that deliver real value.
The US pharmaceutical industry argues that high prices fund research and innovation. Yet the data tell a different story. A 2021 study in the Journal of the American Medical Association found that the top 15 pharmaceutical companies spent more on marketing and executive compensation than on research and development. Meanwhile, public funding through the National Institutes of Health underwrites much of the basic science that leads to breakthrough drugs, including the development of GLP-1 receptor agonists like semaglutide. The US taxpayer pays twice: once for the research, and again through inflated prices.
Canada’s success with generic Ozempic is not an isolated event. It is part of a broader trend where countries with rational drug pricing policies are outperforming the US in access to essential medicines. Australia, Japan, and most European nations have similar mechanisms. The result is that a diabetic in the UK or Canada is far more likely to receive optimal treatment than one in the US, despite the US spending more per capita on healthcare than any other country.
The implications for the global energy transition are indirect but relevant. The same market failures that drive inequality in drug access also hinder the adoption of clean energy technologies. Both sectors are dominated by entrenched interests that rely on patent protections and regulatory capture to maintain high prices. As the world races to decarbonise, lessons from healthcare procurement can inform policies to make solar panels, batteries, and electric vehicles affordable for all.
The NHS model is not without flaws. It can be slow to adopt new drugs, and NICE’s cost thresholds sometimes deny treatments to patients with rare conditions. However, for widespread diseases like diabetes and obesity, the system works. The UK has lower rates of diabetes complications and obesity-related hospitalisations than the US, partly due to better access to medications.
There is a palpable sense of calm urgency in this story. The planet is warming, and chronic diseases are rising. Both crises require rational, coordinated responses. Canada’s generic Ozempic is a small but powerful signal: when governments put patients before profits, access improves. The US can no longer afford to ignore this lesson. Its pharmaceutical pricing is a fossil fuel of the healthcare system: expensive, damaging, and ultimately unsustainable. The transition to a more equitable model is not only possible but necessary. The NHS and Canada have shown the way. Now it is time for the United States to follow.
